Dit is het persbericht van op de website van Spineway:
After a dynamic 2nd quarter, Spineway consolidated its growth in Q3 with revenues of €1.1m, an
improvement or 22% as compared to Q3 2020, bringing 9-month activity to 2.9m (+27%). The Group is thus
seeing an increase in its sales activity across all of its operating regions, excluding the USA. Moreover, the
more favourable sales mix, oriented towards implants and higher value-added product lines, should
contribute to improving the Group’s margins.
Latin America remains the Group’s leading contributor (48% of Group sales) and saw its sales at the end of
September rise to €1.4m, i.e., an increase of +39% as compared to the same period last year.
Sales in Europe amounted to €0.6m, up 19%, driven by the integration of Distimp in June 2021.
Asia (21% of Group sales) grew by 22% at the end of September with sales of €0.6m.
To date, Spineway’s cash position amounts to €15m1
, which reinforces the Group’s investment capacity to
pursue its strategic plan of becoming a European spinal surgery specialist. Spineway remains attentive to any
external growth opportunity that could offer value-creating synergies through a strengthening of its positions
or a diversification of its implant range.
Despite the on-going pandemic situation in some regions of the world, a solid cash position and a good
business trend as compared to 2020 is allowing Spineway to continue reorganizing and structuring its
teams to support the deployment of its strategic plan.